Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases

REFERENCES

1. 1.↵
   1. Avouac J,
   2. Drumez E,
   3. Hachulla E, et al.

   COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-26.

   OpenUrlPubMed
2. 2.↵
   1. Strangfeld A,
   2. Schäfer M,
   3. Gianfrancesco MA, et al.

   Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80:930-42.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Bachiller-Corral J,
   2. Boteanu A,
   3. Garcia-Villanueva MJ, et al.

   Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases. J Rheumatol 2021;48:1098-102.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Westra J,
   2. van Assen S,
   3. Wilting KR, et al.

   Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 2014;178:40-7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Ammitzbøll C,
   2. Bartels LE,
   3. Andersen JB, et al.

   Impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 2021;3:622-8.

   OpenUrl
6. 6.↵
   1. Magliulo D,
   2. Wade SD,
   3. Kyttaris VC.

   Immunogenicity of SARS-CoV2 vaccination in rituximab-treated patients: effect of timing and immunologic parameters. Clin Immunol 2021;234:108897.

   OpenUrl
7. 7.↵
   1. Ferri C,
   2. Ursini F,
   3. Gragnani L, et al.

   Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun 2021;125:102744.

   OpenUrl
8. 8.↵
   1. Avouac J,
   2. Miceli-Richard C,
   3. Combier A, et al.

   Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients. Rheumatology 2021 Nov 2 (Epub ahead of print).
9. 9.↵
   1. Thiel J,
   2. Rizzi M,
   3. Engesser M, et al.

   B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 2017;19:101.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Furer V,
    2. Rondaan C,
    3. Heijstek MW, et al.

    2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39-52.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Houot R,
    2. Levy R,
    3. Cartron G,
    4. Armand P.

    Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer 2020;136:4-6.

    OpenUrlPubMed
12. 12.↵
    1. Prendecki M,
    2. Clarke C,
    3. Edwards H, et al.

    Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322-9.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Bonelli MM,
    2. Mrak D,
    3. Perkmann T,
    4. Haslacher H,
    5. Aletaha D.

    SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021:80:1355-6.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Furer V,
    2. Eviatar T,
    3. Zisman D, et al.

    Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330-8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Harritshøj LH,
    2. Gybel-Brask M,
    3. Afzal S, et al.

    Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol 2021;59:e02596-20.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Herishanu Y,
    2. Avivi I,
    3. Aharon A, et al.

    Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165-73.

    OpenUrlPubMed
17. 17.↵
    1. Gallo A,
    2. Capuano R,
    3. Donnarumma G, et al.

    Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neurol Sci 2021;42:3523-6.

    OpenUrl
18. 18.↵
    1. Park JK,
    2. Lee YJ,
    3. Shin K, et al.

    Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018;77:898-904.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. McMahan K,
    2. Yu J,
    3. Mercado NB, et al.

    Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630-4.

    OpenUrlCrossRefPubMed